SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-022556
Filing Date
2021-02-16
Accepted
2021-02-16 06:21:50
Documents
18
Period of Report
2021-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm216500d1_8k.htm   iXBRL 8-K 42741
2 EXHIBIT 1.1 tm216500d1_ex1-1.htm EX-1.1 220550
3 EXHIBIT 5.1 tm216500d1_ex5-1.htm EX-5.1 11477
4 EXHIBIT 99.1 tm216500d1_ex99-1.htm EX-99.1 10047
5 EXHIBIT 99.2 tm216500d1_ex99-2.htm EX-99.2 10789
9 GRAPHIC logo.jpg GRAPHIC 3800
10 GRAPHIC ex5-1image_001.jpg GRAPHIC 2536
  Complete submission text file 0001104659-21-022556.txt   548001

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA plx-20210211.xsd EX-101.SCH 3184
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE plx-20210211_lab.xml EX-101.LAB 34592
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plx-20210211_pre.xml EX-101.PRE 22710
11 EXTRACTED XBRL INSTANCE DOCUMENT tm216500d1_8k_htm.xml XML 3602
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 21632003
SIC: 2836 Biological Products, (No Diagnostic Substances)